Clinical Trials Logo

Clinical Trial Summary

Primary cytoreductive surgery for ovarian cancer is an ideal setting to evaluate endothelial function under ANH and AHH, as the procedure is associated with moderately high blood loss. As the technique has not yet been described in this setting, investigators designed a pilot study to evaluate ANH and AHH in patients planned to undergo primary cytoreduction during perioperative period, with the intent of proceeding to a randomized trial if results were favorable.


Clinical Trial Description

Using a computer-generated random number table, patients were randomized to three groups: Control Group(n=30), ANH Group(n=30) and AHH Group(n=30). Patients underwent standard preoperative preparation for cytoreductive surgery according to institutional standards.All patients who underwent a standard anesthesia protocol and similar surgical procedures were considered for the analysis. For this purpose, investigators only included patients who underwent the following interventions: radical hysterectomy, bilateral adnexectomy, one or more bowel resection, peritonectomy, pelvic lymphadenectomy and extended periaortic lymphadenectomy. The patient would be ruled out of the experiment when the participant was accompanied with any kind of serious complications such as wakening delay and drug allergy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06103214
Study type Interventional
Source Zhejiang Cancer Hospital
Contact
Status Completed
Phase N/A
Start date January 1, 2017
Completion date January 31, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06466382 - OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy N/A
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) Phase 1/Phase 2
Recruiting NCT05960630 - MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer N/A
Recruiting NCT04111978 - MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) Phase 3
Recruiting NCT03509246 - Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients Phase 2
Recruiting NCT04402333 - Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival
Recruiting NCT04780945 - Functional Analysis of BRCAness Phase 2
Recruiting NCT03015376 - Inherited Susceptible Genes Among Epithelial Ovarian Cancer
Recruiting NCT03883542 - Sub-type Specific Genomic Mutations in sBOTs
Recruiting NCT05605535 - Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Phase 2